|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.10.25 - 13:03
|
Immatics Appoints Venkat Ramanan as Chief Financial Officer (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer (“CFO”), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos Therapeutics, a Novartis company, where he served as CFO. He will succeed Immatics' current CFO, Arnd Christ.“We are thrilled to welcome Venkat to Immatics as an accomplished and passionate biopharmaceutical leader. His extensive experience will be instrumental in enabling us to continue to advance our PR...
|
|
|
|
|
|
|
25.09.25 - 15:06
|
Dr. Robert Lenz Joins Unlearn as Strategic Advisor (Business Wire)
|
|
|
Lenz brings over 20 years of experience in global R&D leadership to guide Unlearn as it scales to deliver next-generation clinical trial solutionsSAN FRANCISCO--(BUSINESS WIRE)--Unlearn®, a leader in AI solutions for clinical trials, today welcomed Dr. Robert Lenz as a strategic advisor. Dr. Lenz brings over 20 years of global research and development leadership at companies including Amgen, AbbVie, and Neumora, and will advise Unlearn as it expands partnerships with sponsors and regulators. Having pioneered AI-generated digital twins of patients in clinical trials, Unlearn is now building on this foundation with a suite of advanced AI solutions that empower sponsors to accelerate development, optimize studies, and make more informed decisions.
“Rob's career has been dedicated to advancing innovative development strategies at scale,” said Steve Herne, CEO of Unlearn. “His insight and leadership will be invaluable as Unlearn works with sponsors and regulators to bring AI-powered solutions into clin...
|
|
|
|
|
22.09.25 - 15:06
|
Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors (Business Wire)
|
|
|
Veteran operations leader, with experience at Amgen, Novartis, AstraZeneca, and Kite/Gilead brings decades of manufacturing, quality, and supply chain expertise to support Cellares' global IDMO Smart Factory expansionSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the world's first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Chris McDonald to its Advisory Board. McDonald most recently served as Senior Vice President and Global Head of Technical Operations (Tech Ops) at Kite, a Gilead Company, where he oversaw Global Manufacturing, Global Quality, Process Development, and Global Supply Chain across six worldwide sites and more than 3,000 employees. His organization supported viral vector, clinical, and commercial cell therapy operations and played a key role in establishing new manufacturing facilities, scaling capacity, and ensuring cGMP compliance.
Earlier in his 35-year career, McDonald held leadership roles at Amgen, Novartis, and AstraZene...
|
|
|
|
|
22.09.25 - 08:36
|
Tezspire Recommended for Approval in EU for CRSwNP (Cision)
|
|
|
22 September 2025
Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps
Recommendation based on WAYPOINT Phase III trial results showing Tezspire reduced nasal polyp severity and nasal congestion, nearly eliminated the need for surgery and significantly reduced systemic corticosteroid use vs. placebo
AstraZeneca and Amgen's Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
The Committee for Medicinal...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
